- Home
- VVV vs AXSM Comparison
VVV vs AXSM Comparison
Compare VVV & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- AXSM
- Stock Information
- Founded
- VVV 1866
- AXSM 2012
- Country
- VVV United States
- AXSM United States
- Employees
- VVV N/A
- AXSM N/A
- Industry
- VVV Major Chemicals
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- VVV Industrials
- AXSM Health Care
- Exchange
- VVV Nasdaq
- AXSM Nasdaq
- Market Cap
- VVV 4.3B
- AXSM 5.1B
- IPO Year
- VVV 2016
- AXSM 2015
- Fundamental
- Price
- VVV $34.57
- AXSM $105.16
- Analyst Decision
- VVV Buy
- AXSM Strong Buy
- Analyst Count
- VVV 11
- AXSM 15
- Target Price
- VVV $42.55
- AXSM $170.20
- AVG Volume (30 Days)
- VVV 1.8M
- AXSM 612.2K
- Earning Date
- VVV 05-08-2025
- AXSM 05-05-2025
- Dividend Yield
- VVV N/A
- AXSM N/A
- EPS Growth
- VVV 56.15
- AXSM N/A
- EPS
- VVV 2.05
- AXSM N/A
- Revenue
- VVV $1,674,400,000.00
- AXSM $432,157,000.00
- Revenue This Year
- VVV $6.73
- AXSM $63.30
- Revenue Next Year
- VVV $14.93
- AXSM $61.15
- P/E Ratio
- VVV $16.77
- AXSM N/A
- Revenue Growth
- VVV 9.56
- AXSM 72.16
- 52 Week Low
- VVV $31.02
- AXSM $64.11
- 52 Week High
- VVV $48.27
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- VVV 51.57
- AXSM 45.61
- Support Level
- VVV $33.51
- AXSM $101.41
- Resistance Level
- VVV $35.38
- AXSM $106.77
- Average True Range (ATR)
- VVV 0.89
- AXSM 3.18
- MACD
- VVV -0.02
- AXSM -0.23
- Stochastic Oscillator
- VVV 50.36
- AXSM 39.33
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.